seekingalpha.com /1 month ago

Opus Genetics, Inc. (IRD) Presents at Euretina 2026 - Slideshow

Read source
seekingalpha.com /1 month ago

Aldeyra Therapeutics, Inc. (ALDX) Discusses FDRR and FDA Review Process for Reproxalap in Dry Eye Disease - Slideshow

Read source
cafepharma.com /2 weeks ago

Argenx

Argenx Anonymous (not verified) Thu, 11/05/2026 - 18:31 field_thread_url https://cafepharma.com/boards/threads/argenx.665212/ board name...

Read source
cafepharma.com /1 month ago

Argenx

Argenx Anonymous (not verified) Mon, 10/19/2026 - 10:14 field_thread_url https://cafepharma.com/boards/threads/argenx.665212/ board name...

Read source
seekingalpha.com /1 week ago

Lumexa Imaging Holdings, Inc. (LMRI) Q3 2026 Earnings Call Transcript

Read source
seekingalpha.com /1 month ago

GLP-1s: Still Early In The Growth Story

Read source
seekingalpha.com /2 weeks ago

Annexon, Inc. (ANNX) Discusses Vonaprument Phase III ARCHER II Trial in Geographic Atrophy - Slideshow

Read source
pharmexec.com /2 days ago

<![CDATA[Innogen Licenses GLP-1 Therapy Efsubaglutide Alfa to Arcera]]>

Read source
seekingalpha.com /2 weeks ago

GRAIL, Inc. (GRAL) Q3 2026 Earnings Call Transcript

Read source
newswire.com /1 week ago

Green Leaf Innovations (OTC: GRLF) Meets OTCID Disclosure Requirements Following Profitable Q2 2026 Results

Milestone follows Q2 2026 quarterly report filing and includes current financial disclosure, management certification, a verified company profile and transfer agent share reporting...

Read source
investmentwatchblog.com /1 month ago

ER-100 – aging reversal drug first test results in the EYE with Glaucoma announced

Safety phase. 2 of 3 patients given LOW DOSES reported vision improvement. Phase 2 – Doses will now triple in size for next round. Today, at the American Academy of Ophthalmology A...

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.